Resumen de Sparrow therapeutics exit strategy
Dzidziso Samuel Kamuriwo, Charles Baden-Fuller
The case focuses on Ken Powers, cofounder and chief executive officer of Sparrow Therapeutics, whose young biotechnology company has reached a critical stage where he has to decide whether or not to sell. The company's three main sets of investors have different priorities: (1) a quick cash sale now, (2) delay sale for about a year if returns are greater, and (3) delay sale for 2 years, build company value, and retain autonomy. What choice would be best for the company, for its investors�and for Ken himself? And when would be the best time to implement the exit strategy?
